Loading...
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
BACKGROUND: Standard treatment with sunitinib for patients with metastatic renal cancer provides an ‘on-off’ schedule (daily administration of a 50-mg capsule for 4 weeks, followed by a 2-week break; consecutive 6-week cycles). We developed an alternative intermittent schedule to reduce the toxicity...
Na minha lista:
| Udgivet i: | Drugs R D |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer International Publishing
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5694422/ https://ncbi.nlm.nih.gov/pubmed/28895069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40268-017-0209-5 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|